TAMPA, Fla. — As Neutra Corp. (OTCQB: NTRR) and other wellness companies prepare for the expected nationwide legalization of cannabis in Canada, an economist at a major investment bank estimates that the country’s cannabis market could surpass USD $7 billion annually.
Marijuana Business Daily reports that Avery Shenfeld, an economist with CIBC World Markets, based the impressive figure on sales numbers on consumption estimates for Colorado and Canada. Canadian legalization has been seen as a foregone conclusion by many industry observers since October, when the nation elected Justin Trudeau as its prime minister. Trudeau made repeated campaign promises to legalize and regulate cannabis for adult use.
Soon, Canada could become the second country in the world after Uruguay to fully legalize the plant, kicking off an enormous boom in investment and business opportunities. NTRR plans to be ready when it happens. $7 billion worth of demand will require a great deal of cannabis crops, and NTRR is working to help ensure consumers have access to top-quality plants grown without the use of harsh chemicals unfit for consumption. Alongside its joint venture partner, Surface to Air Solutions (S2O2), NTRR is working to offer cannabis growers and other businesses a suite of horticultural technologies designed to reduce or eliminate the industry’s reliance upon pesticides to produce healthy crops.
To further capitalize on the projected growth of the Canadian cannabis industry, the company formed another joint venture last month with Vancouver-based Oceanview Health Services Ltd. to help research cutting-edge topical creams, oils, salves, lotions and other products that have been infused with medicinal cannabis. Oceanview is currently preparing to debut a new brand of cannabis-infused topical products, BeKind Topicals, in markets where cannabis is legal and regulated.
About Neutra Corp.
Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp. (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Chris Brown, 813-367-2041
President and CEO